sotorasib,fda,lumakras amgen 510,non-small cell lung cancer
Published 3 years ago • 2.2K plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
1:58
sotorasib for advanced non-small cell lung cancer
-
0:37
amgen’s tarlatamab gets fda priority review for small cell lung cancer
-
0:29
u.s. fda approves amgen’s targeted immunotherapy for adults w/extensive-stage small cell lung cancer
-
2:53
kras g12c inhibition in advanced nsclc: mrtx849
-
6:04:50
oncologic drugs advisory committee meeting
-
1:18:54
targeting kras g12c: amgen's breakthrough treatment - insights from i-fen chang and terri conneran
-
5:36
sotorasib demonstrates superior pfs vs docetaxel for previously treated non-small cell lung canc...
-
7:51
kras g12c inhibition in advanced nsclc: amg 510
-
6:22
sotorasib for kras g12c mutated advanced non-small cell lung cancer
-
3:52
deborah’s experience with non-small cell lung cancer
-
1:08
how will adagrasib fit into the treatment landscape of krasg12-mutant nsclc?
-
2:59
sotorasib outperforms docetaxel in previously treated kras-mutated nsclc | melissa johnson
-
2:53
desiree’s perspective after non-small cell lung cancer
-
4:13
sotorasib vs. adagrasib as treatment for kras g12c mutated nsclc - case based panel discussion
-
2:17
learning more about kras lung cancer
-
4:31
esmo22 -lba10 - sotorasib vs docetaxel for previously treated nsclc with kras g12c mutation - co...
-
1:42
treating kras g12c mutations
-
0:17
amgen's late-stage data for lung cancer drug 'not adequate' - fda staff|shorts
-
5:34
researcher comment: amg 510 for kras mutation-positive nsclc | ramaswamy govindan